FDA
-
-
-
-
-
-
-
Leerink Partners Downgrades Gossamer Bio Inc. (GOSS) to Market Perform
-
-
-
-
-
-
-
Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On‑Demand Vardenafil for Pulmonary Hypertension
-
-
-
-
-
-
-
Gossamer Bio Inc. (GOSS) announces FDA has placed a partial clinical hold on all trials of GB5121 in response to serious adverse events
-
-
-
-
-
-
-
Gossamer Bio(GOSS) Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis Did Not Achieve Statistical Significance on Primary Endpoint
-
-
-
-
-
-
-
Gossamer Bio Announces Third Quarter 2019 Financial Results
-
-
-
322,900 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

